• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/

    A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding companies through complex growth trajectories. Most recently, he served as CEO of DeFi Technologies, a publicly traded company at the forefront of decentralized finance and digital asset innovation where he led the company's growth from $0.07 USD to $4.95 USD per share and over $200M USD in yearly revenue. Under his leadership, DeFi Technologies accelerated its strategic focus on Web3 infrastructure, emerging markets, and tokenized finance. After stepping back as CEO of Defi Mr Starr assume the role of Head of Capital Markets and helped bring Defi Technologies to be listed on the Nasdaq.

    Mr. Starr's career is defined by a consistent focus on long-term value creation, particularly in the natural resource and renewable energy sectors. He is a strong advocate for Canada's emerging leadership in the global resource economy and sees the convergence of the renewable energy transition and weakening fiat currencies as powerful tailwinds for real asset investment.

    Over the course of his career, Mr. Starr has held key leadership roles across public and private companies, contributing deep expertise in M&A, venture capital, and strategic partnerships. His ability to structure high-return, high-impact deals has earned him the trust of stakeholders across sectors.

    "Russell's experience in capital markets, natural resources, and decentralized finance make him an exceptional addition to the Streamex advisory team," said Henry McPhie, CEO of BioSig and Co-Founder of Streamex. "His visionary leadership and belief in the long-term value of real assets align perfectly with our mission to bring commodities on chain. We're thrilled to welcome him as we scale our presence in the tokenized asset space."

    Mr. Starr commented, "Streamex is leading a powerful shift in how real-world assets are accessed, valued, and exchanged. The infrastructure they're building is unlocking the full potential of tokenized commodities. I'm excited to contribute to a platform that combines deep market knowledge with a bold, innovative vision."

    Streamex's Advisory Board

    Russell Starr joins a world-class group of strategic advisors at Streamex:

    • Frank Giustra – Strategic Investor and Advisor on Commodities
      • Founder of Wheaton Precious Metals ($37B)
      • Founder of GoldCorp (Acquired by Newmont for $57B)
      • Founder of LionsGate Films ($2B)
    • Sean Roosen – Strategic Advisor on Mining and Asset Strategy
      • Founder, Executive Chairman, and CEO of Osisko Development Corp.
      • Founder & Former CEO of Osisko Mining
      • Founder & Former CEO of Osisko Gold Royalties ($6.9B)
    • Mathew August – Strategic Advisor on US Capital Markets
      • Executive Chairman of Atlas Capital Partners, a New York-based single-family office and merchant bank
      • Active venture capitalist with investments in Defense Tech, FinTech, and Aerospace
    • Russell Starr – Strategic Advisor on Defi & Resource Innovation
      • Former CEO of DeFi Technologies
      • Veteran Bay Street executive and capital markets expert
      • Entrepreneur specializing in high-return transactions, renewable energy, and natural resources
    • Trevor Bacon – Strategic Advisor on DeFi Infrastructure
      • CEO and Co-Founder of Parcl
      • Former Portfolio Manager and Barclays Vice President
    • Kellan Grenier – Strategic Advisor on Tokenized Asset Strategy and Web3 Integration
      • COO and Co-Founder of Parcl
      • Former Investment Analyst and blockchain strategist

    About Streamex

    Streamex is a gold treasury and infrastructure company building the foundation for on-chain commodity markets. With a focus on real-world asset (RWA) tokenization, Streamex is developing a vertically integrated platform that combines token issuance, trading infrastructure, and physical gold holdings positioning the Company to become one of Nasdaq's largest public holders of gold bullion.

    This strategic approach aligns with Streamex's mission to reshape global finance by bringing the approximately $142 trillion global commodities market on chain. By merging the security and trust of physical gold with the efficiency and transparency of blockchain, Streamex is creating scalable financial infrastructure for a new era of digital commodities.

    The Company plans to hold significant quantities of physical gold, securely vaulted through a top-tier bullion bank. Streamex will denominate the majority of its balance sheet in vaulted gold rather than fiat currency, supporting a long-term, value-based financial model. Combined with Streamex's Solana-based blockchain infrastructure, this strategy enables a recurring revenue model that supports the issuance of gold-backed digital assets.

    Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained, and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250711280588/en/

    [email protected]

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    SEC Filings

    View All

    BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 5:15:46 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by BioSig Technologies Inc.

    10-Q - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:53:03 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFR14A filed by BioSig Technologies Inc.

    DEFR14A - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:15:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on BioSig Technologies with a new price target

    The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

    2/8/21 7:32:50 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Financials

    Live finance-specific insights

    View All

    BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

    Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

    9/22/22 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig to Host Conference Call on December 21, 2021

    Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

    12/13/21 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

    Los Angeles, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), a gold tokenization infrastructure company, today announced the closing of its previously announced underwritten public offering, including a group of technology and mining thought leaders. The offering consisted of 3,852,149 shares of common stock at a public offering price of $3.90 per share with no pre-funded warrants. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses were approximately $15,023,381. The Company inte

    8/15/25 4:50:14 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offerin

    8/13/25 11:10:13 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Proposed Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company") which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, fo

    8/13/25 5:16:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    View All

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

    Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

    6/9/25 10:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

    Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

    6/4/25 8:25:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:31:07 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mcphie Karl Henry Michael

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:29:42 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Lekstrom Morgan Lee

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:27:01 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by BioSig Technologies Inc.

    SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

    2/14/24 3:31:45 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    7/12/21 8:29:21 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care